As appeared in Thomson Reuters’ “Alison Frankel’s ON THE CASE” Column
A judge in the Pfizer v. Teva Pharmaceuticals patent case awarded attorney fees to Pfizer. According to Kaye Scholer Partner Aaron Stiefel, the ruling sends a message about the consequences of asserting an unfounded inequitable conduct claim.
“This should have something of a chilling effect,” he said.
Referring to the exception for egregious misconduct, in the Therasense case, apparently relied upon by the opposing party Teva Pharmaceuticals, Stiefel added, “You can’t just say, ‘We’re within the exception and we have a right to litigate this.’”
Stiefel explained that such a broad interpretation of the Therasense exception would have undermined the Federal Circuit’s objective of curtailing dubious misconduct allegations.
As to whether he is worried about a Federal Circuit review of the award, Stiefel concluded, “Reading Therasense, you would think the Federal Circuit would appreciate [the judge’s] decision.”
Also of Interest
- NLJ Names Shores as Antitrust Trailblazer September 27, 2016 • Recognitions
- Shape of Things to Come: Protecting Product Configuration and Packaging Design September 26, 2016 • Articles
- On the Road to a Safe and Secure Internet of Things: What Companies Should Do September 19, 2016 • Articles
- Druckenbrodt Quoted in Bloomberg on Volkswagen Dieselgate September 14, 2016 • Media Mentions
- Arbisser Featured in The Recorder and Law360... September 7, 2016 • Media Mentions
- Consumer Products: Adapting to Innovation Fall 2016 • Reports / Newsletters
- Kaye Scholer Secures Dismissal of Merger-Related Class Action Against Baltic Trading September 1, 2016 • Client Successes
- Following Five-Day Trial, Kaye Scholer Secures Win for Medicalgorithmics August 25, 2016 • Client Successes
- Doing Deals with Competitors: Beware of Taking Minority Equity Stakes or Board Seats August 24, 2016 • Articles